{ "disease": "chronic-lymphocytic-leukemia", "label": "Chronic lymphocytic leukemia", "url": "https://usebiotransfer.org/disease/chronic-lymphocytic-leukemia/", "built": "2026-09-12", "facts_hash": { "answers": "0203cfd66101", "targets": "b8f4337ef542" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "BTK", "ensembl": "ENSG00000010671", "n_drug_entries": 24, "n_distinct_drugs": 20, "drugs": { "ABIVERTINIB": "PHASE_3", "ACALABRUTINIB": "APPROVAL", "BMS-986142": "PHASE_2", "BRANEBRUTINIB": "PHASE_2", "EDRALBRUTINIB": "PHASE_2", "ELSUBRUTINIB": "PHASE_2", "EVOBRUTINIB": "PHASE_3", "FENEBRUTINIB": "PHASE_3", "IBRUTINIB": "APPROVAL", "MSC-2364447": "PHASE_1", "ORELABRUTINIB": "APPROVAL", "PIRTOBRUTINIB": "APPROVAL", "POSELTINIB": "PHASE_2", "RILZABRUTINIB": "APPROVAL", "RITLECITINIB": "APPROVAL", "SPEBRUTINIB": "PHASE_2", "TIRABRUTINIB": "APPROVAL", "TOLEBRUTINIB": "PREAPPROVAL", "VECABRUTINIB": "PHASE_1_2", "ZANUBRUTINIB": "APPROVAL" }, "approved": [ "ACALABRUTINIB", "IBRUTINIB", "ORELABRUTINIB", "PIRTOBRUTINIB", "RILZABRUTINIB", "RITLECITINIB", "TIRABRUTINIB", "ZANUBRUTINIB" ], "n_approved": 8, "approved_for": { "ACALABRUTINIB": [ "B-cell chronic lymphocytic leukemia", "childhood leukemia", "mantle cell lymphoma" ], "IBRUTINIB": [ "macroglobulinemia", "mantle cell lymphoma", "B-cell chronic lymphocytic leukemia" ], "ORELABRUTINIB": [], "PIRTOBRUTINIB": [ "mantle cell lymphoma", "non-Hodgkin lymphoma" ], "RILZABRUTINIB": [ "autoimmune thrombocytopenic purpura" ], "RITLECITINIB": [ "alopecia areata" ], "TIRABRUTINIB": [], "ZANUBRUTINIB": [ "mantle cell lymphoma", "B-cell chronic lymphocytic leukemia", "lymphoplasmacytic lymphoma", "Waldenstrom macroglobulinemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Phase 1 Clinical" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BCL2", "ensembl": "ENSG00000171791", "n_drug_entries": 7, "n_distinct_drugs": 5, "drugs": { "APG-2575": "PHASE_3", "NAVITOCLAX": "APPROVAL", "OBATOCLAX": "PHASE_3", "OBLIMERSEN": "APPROVAL", "VENETOCLAX": "APPROVAL" }, "approved": [ "NAVITOCLAX", "OBLIMERSEN", "VENETOCLAX" ], "n_approved": 3, "approved_for": { "NAVITOCLAX": [], "OBLIMERSEN": [], "VENETOCLAX": [ "B-cell chronic lymphocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PIK3CD", "ensembl": "ENSG00000171608", "n_drug_entries": 46, "n_distinct_drugs": 42, "drugs": { "ACALISIB": "PHASE_1", "AMG-319": "PHASE_2", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "AZD-8186": "PHASE_1_2", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "CAL-263": "PHASE_1", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "DUVELISIB": "APPROVAL", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "GSK-2269557": "PHASE_2", "IDELALISIB": "APPROVAL", "INCB-40093": "PHASE_2", "IZORLISIB": "PHASE_1_2", "LENIOLISIB": "APPROVAL", "NEMIRALISIB": "PHASE_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PARSACLISIB": "APPROVAL", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SELETALISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "TENALISIB": "PHASE_2", "TG100-115": "PHASE_1_2", "UMBRALISIB": "APPROVAL", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZANDELISIB": "PHASE_3", "ZSTK-474": "PHASE_1" }, "approved": [ "COPANLISIB", "DUVELISIB", "IDELALISIB", "LENIOLISIB", "PARSACLISIB", "UMBRALISIB" ], "n_approved": 6, "approved_for": { "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "DUVELISIB": [ "follicular lymphoma", "B-cell chronic lymphocytic leukemia", "lymphoma", "neoplasm of mature B-cells" ], "IDELALISIB": [ "B-cell chronic lymphocytic leukemia", "neoplasm of mature B-cells", "non-Hodgkin lymphoma" ], "LENIOLISIB": [ "inborn error of immunity", "gastric cancer" ], "PARSACLISIB": [], "UMBRALISIB": [ "follicular lymphoma", "marginal zone lymphoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ATM", "ensembl": "ENSG00000149311", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SF3B1", "ensembl": "ENSG00000115524", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "NOTCH1", "ensembl": "ENSG00000148400", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "BRONTICTUZUMAB": "PHASE_1" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MS4A1", "ensembl": "ENSG00000156738", "n_drug_entries": 18, "n_distinct_drugs": 18, "drugs": { "EPCORITAMAB": "APPROVAL", "FBT-A05": "PHASE_1_2", "GLOFITAMAB": "APPROVAL", "LFB-R603": "PHASE_1", "MOSUNETUZUMAB": "APPROVAL", "MT-3724": "PHASE_2", "OBINUTUZUMAB": "APPROVAL", "OCARATUZUMAB": "PHASE_2", "OCRELIZUMAB": "APPROVAL", "ODRONEXTAMAB": "APPROVAL", "OFATUMUMAB": "APPROVAL", "RITUXIMAB": "APPROVAL", "TOSITUMOMAB": "APPROVAL", "TOSITUMOMAB 131I": "PHASE_3", "TRU-015": "PHASE_2", "UBLITUXIMAB": "APPROVAL", "VELTUZUMAB": "PHASE_2", "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL" }, "approved": [ "EPCORITAMAB", "GLOFITAMAB", "MOSUNETUZUMAB", "OBINUTUZUMAB", "OCRELIZUMAB", "ODRONEXTAMAB", "OFATUMUMAB", "RITUXIMAB", "TOSITUMOMAB", "UBLITUXIMAB", "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN" ], "n_approved": 11, "approved_for": { "EPCORITAMAB": [ "follicular lymphoma", "B-cell non-Hodgkin lymphoma", "diffuse large B-cell lymphoma" ], "GLOFITAMAB": [ "diffuse large B-cell lymphoma" ], "MOSUNETUZUMAB": [ "follicular lymphoma" ], "OBINUTUZUMAB": [ "follicular lymphoma", "B-cell chronic lymphocytic leukemia" ], "OCRELIZUMAB": [ "multiple sclerosis", "diffuse large B-cell lymphoma", "relapsing-remitting multiple sclerosis", "chronic progressive multiple sclerosis" ], "ODRONEXTAMAB": [ "follicular lymphoma" ], "OFATUMUMAB": [ "relapsing-remitting multiple sclerosis", "B-cell chronic lymphocytic leukemia", "multiple sclerosis", "secondary progressive multiple sclerosis" ], "RITUXIMAB": [ "non-Hodgkin lymphoma", "granulomatosis with polyangiitis", "B-cell chronic lymphocytic leukemia", "acute lymphoblastic leukemia", "rheumatoid arthritis", "microscopic polyangiitis", "pemphigus", "vasculitis" ], "TOSITUMOMAB": [ "non-Hodgkin lymphoma" ], "UBLITUXIMAB": [ "multiple sclerosis", "relapsing-remitting multiple sclerosis", "chronic progressive multiple sclerosis" ], "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [ "follicular lymphoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "CD19", "ensembl": "ENSG00000177455", "n_drug_entries": 14, "n_distinct_drugs": 14, "drugs": { "AXICABTAGENE CILOLEUCEL": "APPROVAL", "BLINATUMOMAB": "APPROVAL", "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL", "COLTUXIMAB RAVTANSINE": "PHASE_2", "DENINTUZUMAB MAFODOTIN": "PHASE_2", "INEBILIZUMAB": "APPROVAL", "LISOCABTAGENE MARALEUCEL": "APPROVAL", "LONCASTUXIMAB TESIRINE": "APPROVAL", "MDX-1342": "PHASE_2", "OBECABTAGENE AUTOLEUCEL": "APPROVAL", "OBEXELIMAB": "PHASE_3", "ONCOLYSIN B": "PHASE_2", "TAFASITAMAB": "APPROVAL", "TISAGENLECLEUCEL": "APPROVAL" }, "approved": [ "AXICABTAGENE CILOLEUCEL", "BLINATUMOMAB", "BREXUCABTAGENE AUTOLEUCEL", "INEBILIZUMAB", "LISOCABTAGENE MARALEUCEL", "LONCASTUXIMAB TESIRINE", "OBECABTAGENE AUTOLEUCEL", "TAFASITAMAB", "TISAGENLECLEUCEL" ], "n_approved": 9, "approved_for": { "AXICABTAGENE CILOLEUCEL": [ "diffuse large B-cell lymphoma", "follicular lymphoma" ], "BLINATUMOMAB": [ "acute lymphoblastic leukemia", "B-cell acute lymphoblastic leukemia", "lymphoid leukemia" ], "BREXUCABTAGENE AUTOLEUCEL": [ "mantle cell lymphoma" ], "INEBILIZUMAB": [ "neuromyelitis optica" ], "LISOCABTAGENE MARALEUCEL": [ "diffuse large B-cell lymphoma", "follicular lymphoma", "neoplasm of mediastinum" ], "LONCASTUXIMAB TESIRINE": [ "diffuse large B-cell lymphoma", "B-cell neoplasm", "B-cell non-Hodgkin lymphoma" ], "OBECABTAGENE AUTOLEUCEL": [ "B-cell acute lymphoblastic leukemia" ], "TAFASITAMAB": [ "diffuse large B-cell lymphoma", "lymphoma" ], "TISAGENLECLEUCEL": [ "diffuse large B-cell lymphoma" ] }, "tractability": [ { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "ROR1", "ensembl": "ENSG00000185483", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "CIRMTUZUMAB": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "CD52", "ensembl": "ENSG00000169442", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "ALEMTUZUMAB": "APPROVAL", "ALEMTUZUMAB BETA": "UNKNOWN" }, "approved": [ "ALEMTUZUMAB" ], "n_approved": 1, "approved_for": { "ALEMTUZUMAB": [ "B-cell chronic lymphocytic leukemia", "multiple sclerosis" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" } ] }, { "symbol": "MYD88", "ensembl": "ENSG00000172936", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] } ], "trials": { "by_antigen": { "CD20": { "n": 432, "n_observational": 32, "n_active": 95, "n_withdrawn": 23, "trials": [ { "nct": "NCT02727803", "title": "Personalized NK Cell Therapy in CBT", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516617", "title": "Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03986034", "title": "Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04269902", "title": "Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523428", "title": "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04679012", "title": "Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895436", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908228", "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-na\u00efve Patients With CLL", "status": "RECRUITING", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010564", "title": "Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05131022", "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05418088", "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950997", "title": "A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL", "status": "RECRUITING", "last_update": "2024-05-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043674", "title": "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333262", "title": "Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508775", "title": "Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06542250", "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544785", "title": "Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644183", "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735664", "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation", "status": "RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839053", "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06916767", "title": "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06978088", "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07108998", "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139873", "title": "A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218510", "title": "Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07520006", "title": "Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00001586", "title": "Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis", "status": "COMPLETED", "last_update": "2013-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "status": "COMPLETED", "last_update": "2023-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003204", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003248", "title": "Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003356", "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003605", "title": "Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003659", "title": "Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003663", "title": "Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003963", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004040", "title": "Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004112", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005601", "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00007852", "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012207", "title": "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2010-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012298", "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022971", "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00033423", "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00048737", "title": "Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2013-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058227", "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058292", "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062296", "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00067002", "title": "Randomized Double Cord Blood Transplant Study", "status": "COMPLETED", "last_update": "2019-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071396", "title": "Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072514", "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080886", "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086203", "title": "Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086775", "title": "Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00087425", "title": "Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00090051", "title": "FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00093314", "title": "HuMax-CD20 in Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2015-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103558", "title": "Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104858", "title": "Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00119392", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00131313", "title": "Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.", "status": "UNKNOWN", "last_update": "2005-08-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143065", "title": "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143559", "title": "Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies", "status": "COMPLETED", "last_update": "2009-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00145613", "title": "Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies", "status": "COMPLETED", "last_update": "2009-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00201682", "title": "Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00201721", "title": "Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244946", "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244985", "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00254410", "title": "FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years", "status": "COMPLETED", "last_update": "2019-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265915", "title": "Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2014-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265928", "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2008-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274989", "title": "Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00275054", "title": "Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00280241", "title": "Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281918", "title": "Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281983", "title": "Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2017-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00286780", "title": "Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2010-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00288067", "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2014-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330252", "title": "Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337246", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343447", "title": "Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2012-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349349", "title": "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab", "status": "COMPLETED", "last_update": "2014-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00366418", "title": "Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381004", "title": "FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00383994", "title": "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2019-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00391066", "title": "Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410163", "title": "Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients", "status": "COMPLETED", "last_update": "2014-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410982", "title": "Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00438880", "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00448019", "title": "FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00473551", "title": "Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2011-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476229", "title": "Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496873", "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00504491", "title": "R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2011-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513747", "title": "Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2020-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517218", "title": "This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)", "status": "WITHDRAWN", "last_update": "2008-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525603", "title": "CFAR Study in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00532129", "title": "A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2016-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536341", "title": "Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2017-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00543114", "title": "Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL", "status": "TERMINATED", "last_update": "2016-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00545714", "title": "A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546377", "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546793", "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL", "status": "COMPLETED", "last_update": "2021-08-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551239", "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00564512", "title": "Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP", "status": "COMPLETED", "last_update": "2013-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577278", "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan", "status": "COMPLETED", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00601718", "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00602459", "title": "Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00602836", "title": "Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00612612", "title": "Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621452", "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00625729", "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00628238", "title": "Multi-center Trial of Revlimid\u00ae and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)", "status": "UNKNOWN", "last_update": "2010-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00636155", "title": "EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2012-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00645606", "title": "Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691652", "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695786", "title": "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738374", "title": "A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738829", "title": "Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL", "status": "COMPLETED", "last_update": "2013-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00742144", "title": "Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00748189", "title": "Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00758693", "title": "Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)", "status": "WITHDRAWN", "last_update": "2012-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759603", "title": "Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759798", "title": "Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00764517", "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "status": "TERMINATED", "last_update": "2015-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783367", "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00788684", "title": "Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers", "status": "COMPLETED", "last_update": "2025-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00801060", "title": "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00802737", "title": "Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-05-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00824265", "title": "Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860457", "title": "Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00867529", "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma", "status": "COMPLETED", "last_update": "2018-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00877214", "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas", "status": "UNKNOWN", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00880815", "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant", "status": "COMPLETED", "last_update": "2019-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00892827", "title": "Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2010-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00939328", "title": "S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment", "status": "WITHDRAWN", "last_update": "2015-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00946023", "title": "Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab", "status": "TERMINATED", "last_update": "2018-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00974233", "title": "Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL", "status": "COMPLETED", "last_update": "2019-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00991211", "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01002755", "title": "Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010061", "title": "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010217", "title": "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide", "status": "COMPLETED", "last_update": "2020-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010568", "title": "Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01024010", "title": "Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2018-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01027000", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039376", "title": "Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy", "status": "TERMINATED", "last_update": "2019-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044745", "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer", "status": "TERMINATED", "last_update": "2023-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01056510", "title": "A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01076556", "title": "Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2015-11-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077622", "title": "A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01110031", "title": "Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01113632", "title": "Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2016-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116232", "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation", "status": "TERMINATED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01118234", "title": "Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)", "status": "COMPLETED", "last_update": "2020-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01119794", "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab", "status": "TERMINATED", "last_update": "2015-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123356", "title": "Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab", "status": "COMPLETED", "last_update": "2015-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125176", "title": "Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125787", "title": "Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab", "status": "TERMINATED", "last_update": "2011-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01131247", "title": "PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab", "status": "WITHDRAWN", "last_update": "2011-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138579", "title": "Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145209", "title": "Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL", "status": "COMPLETED", "last_update": "2023-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01171378", "title": "Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome", "status": "COMPLETED", "last_update": "2018-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01181258", "title": "Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2018-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191190", "title": "Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217749", "title": "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01239394", "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01243190", "title": "Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01244451", "title": "GIMEMA CLL0809 Study (BendOfa)", "status": "COMPLETED", "last_update": "2019-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253460", "title": "Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)", "status": "TERMINATED", "last_update": "2019-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01258933", "title": "Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy", "status": "TERMINATED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01263704", "title": "A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01283386", "title": "A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status", "status": "TERMINATED", "last_update": "2019-03-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01290549", "title": "A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma", "status": "COMPLETED", "last_update": "2017-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292135", "title": "Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292603", "title": "A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300247", "title": "A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)", "status": "COMPLETED", "last_update": "2017-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01310101", "title": "Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01313689", "title": "Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326702", "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01352312", "title": "Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma", "status": "TERMINATED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361711", "title": "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "status": "COMPLETED", "last_update": "2017-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01369849", "title": "Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01370772", "title": "Intensified Rituimab Prephase Before FCR in Untreated B-CLL", "status": "COMPLETED", "last_update": "2016-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01373229", "title": "Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01381692", "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01410513", "title": "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01414205", "title": "A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)", "status": "COMPLETED", "last_update": "2017-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01416974", "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab", "status": "COMPLETED", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419795", "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01424982", "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01444716", "title": "Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01455051", "title": "Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation", "status": "COMPLETED", "last_update": "2022-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01465230", "title": "Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2014-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471067", "title": "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2017-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01490723", "title": "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)", "status": "COMPLETED", "last_update": "2020-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01496976", "title": "Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497496", "title": "Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2021-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515176", "title": "Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01516580", "title": "Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients", "status": "COMPLETED", "last_update": "2026-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520519", "title": "Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520922", "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)", "status": "COMPLETED", "last_update": "2017-01-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521689", "title": "Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment", "status": "UNKNOWN", "last_update": "2015-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01532700", "title": "An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01539512", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01558167", "title": "A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01563055", "title": "A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576588", "title": "Rituximab in Pretreated Elderly or Unfit B-CLL Patients", "status": "COMPLETED", "last_update": "2019-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580228", "title": "A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)", "status": "COMPLETED", "last_update": "2017-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01611090", "title": "A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612988", "title": "Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL", "status": "TERMINATED", "last_update": "2018-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01619761", "title": "NK Cells in Cord Blood Transplantation", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01625741", "title": "Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy", "status": "TERMINATED", "last_update": "2015-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "status": "TERMINATED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01647971", "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2022-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659021", "title": "Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659047", "title": "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2012-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01670812", "title": "Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2012-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671904", "title": "A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01678430", "title": "A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment", "status": "UNKNOWN", "last_update": "2012-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01680991", "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease", "status": "COMPLETED", "last_update": "2016-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01681563", "title": "Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682044", "title": "Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2017-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682616", "title": "A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685892", "title": "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01716208", "title": "Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723839", "title": "Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01735604", "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy", "status": "UNKNOWN", "last_update": "2015-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744626", "title": "Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2016-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744912", "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2022-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01762202", "title": "Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809847", "title": "Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation", "status": "COMPLETED", "last_update": "2016-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01848145", "title": "Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01868893", "title": "An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "status": "COMPLETED", "last_update": "2016-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01886872", "title": "Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905943", "title": "A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-10-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980875", "title": "Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980888", "title": "Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "status": "COMPLETED", "last_update": "2022-04-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01998880", "title": "CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004522", "title": "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006485", "title": "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies", "status": "COMPLETED", "last_update": "2019-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007044", "title": "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013817", "title": "CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02048813", "title": "Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049515", "title": "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02053610", "title": "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02071225", "title": "A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02100852", "title": "TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135133", "title": "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137889", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients", "status": "TERMINATED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02144623", "title": "Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02160015", "title": "Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02168907", "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02186574", "title": "Tenofovir to Prevent HBV Reactivation", "status": "UNKNOWN", "last_update": "2019-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213913", "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02225275", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02229422", "title": "A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)", "status": "UNKNOWN", "last_update": "2023-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02232386", "title": "Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242942", "title": "Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02251548", "title": "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257242", "title": "Vincristine Sulfate Liposome Injection (Marqibo\u00ae), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma", "status": "COMPLETED", "last_update": "2023-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02259348", "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation", "status": "TERMINATED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264574", "title": "A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na\u00efve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02265731", "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02280525", "title": "Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma", "status": "COMPLETED", "last_update": "2023-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02292225", "title": "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)", "status": "TERMINATED", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315118", "title": "Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315768", "title": "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320487", "title": "A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336048", "title": "A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities", "status": "TERMINATED", "last_update": "2021-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02339922", "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02361346", "title": "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02371590", "title": "Lenalidomide and Obinutuzumab for Previously Untreated CLL", "status": "WITHDRAWN", "last_update": "2018-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02384954", "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab", "status": "TERMINATED", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02388048", "title": "Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02420938", "title": "Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients", "status": "WITHDRAWN", "last_update": "2016-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475681", "title": "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02535286", "title": "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation", "status": "COMPLETED", "last_update": "2022-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537613", "title": "A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02556346", "title": "Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2016-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02594384", "title": "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611908", "title": "Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.", "status": "WITHDRAWN", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02612311", "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614508", "title": "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2017-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629809", "title": "Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657447", "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "status": "TERMINATED", "last_update": "2024-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02666898", "title": "Phase II Trial GA101 Inbrutinib B CLL", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689141", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)", "status": "COMPLETED", "last_update": "2020-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846584", "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846623", "title": "Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924402", "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies", "status": "COMPLETED", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02933320", "title": "BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia", "status": "COMPLETED", "last_update": "2021-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02960646", "title": "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2023-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968563", "title": "Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983617", "title": "Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003546", "title": "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010358", "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019055", "title": "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03096782", "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma", "status": "COMPLETED", "last_update": "2023-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125577", "title": "Combination CAR-T Cell Therapy Targeting Hematological Malignancies", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153514", "title": "Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2022-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277729", "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280160", "title": "Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab", "status": "UNKNOWN", "last_update": "2022-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03398967", "title": "A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2018-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03524235", "title": "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576547", "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576807", "title": "The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma", "status": "UNKNOWN", "last_update": "2018-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639324", "title": "Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL", "status": "WITHDRAWN", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03759184", "title": "Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia", "status": "TERMINATED", "last_update": "2022-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03788291", "title": "Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "status": "TERMINATED", "last_update": "2024-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823365", "title": "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016129", "title": "CAR-T Immunotherapy Targeting CD19- ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04030195", "title": "Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL", "status": "COMPLETED", "last_update": "2023-01-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059081", "title": "A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment", "status": "UNKNOWN", "last_update": "2019-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155840", "title": "Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156178", "title": "CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160195", "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2022-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04176913", "title": "Study of LUCAR-20S in Patients With R/R NHL", "status": "TERMINATED", "last_update": "2022-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245722", "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies", "status": "TERMINATED", "last_update": "2023-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260945", "title": "CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285567", "title": "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419519", "title": "Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434196", "title": "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447768", "title": "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458610", "title": "Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04505254", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542824", "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578600", "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578613", "title": "ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL", "status": "UNKNOWN", "last_update": "2023-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04688385", "title": "Personalized Multi-peptide Vaccination in CLL Patients", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722172", "title": "A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04843904", "title": "Safe Accelerated Venetoclax Escalation in CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923048", "title": "A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.", "status": "UNKNOWN", "last_update": "2023-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04981912", "title": "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05003141", "title": "PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2022-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069051", "title": "Belimumab in Patients with Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094206", "title": "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209308", "title": "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL", "status": "WITHDRAWN", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322733", "title": "Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL", "status": "UNKNOWN", "last_update": "2022-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360238", "title": "Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL", "status": "TERMINATED", "last_update": "2024-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424822", "title": "A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05797233", "title": "Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06291220", "title": "A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547944", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06970743", "title": "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003464", "title": "Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166419", "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166549", "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624799", "title": "Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674810", "title": "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690891", "title": "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07753369", "title": "A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 35, "n_observational": 0, "n_active": 12, "n_withdrawn": 2, "trials": [ { "nct": "NCT02727803", "title": "Personalized NK Cell Therapy in CBT", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010564", "title": "Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05418088", "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06916767", "title": "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00383994", "title": "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2019-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00473551", "title": "Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2011-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621452", "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138579", "title": "Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "status": "COMPLETED", "last_update": "2017-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01416974", "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab", "status": "COMPLETED", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01619761", "title": "NK Cells in Cord Blood Transplantation", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01735604", "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy", "status": "UNKNOWN", "last_update": "2015-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315118", "title": "Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846584", "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019055", "title": "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125577", "title": "Combination CAR-T Cell Therapy Targeting Hematological Malignancies", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277729", "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03398967", "title": "A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2018-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576807", "title": "The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma", "status": "UNKNOWN", "last_update": "2018-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03759184", "title": "Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia", "status": "TERMINATED", "last_update": "2022-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823365", "title": "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016129", "title": "CAR-T Immunotherapy Targeting CD19- ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156178", "title": "CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160195", "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2022-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260945", "title": "CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094206", "title": "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05797233", "title": "Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166419", "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166549", "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD20", "MS4A1", "rituximab", "obinutuzumab", "ofatumumab" ] }, "CD19": { "n": 183, "n_observational": 3, "n_active": 73, "n_withdrawn": 10, "trials": [ { "nct": "NCT01853631", "title": "Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03263572", "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03676504", "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR", "status": "RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765177", "title": "CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04545762", "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603872", "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies", "status": "RECRUITING", "last_update": "2020-10-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892277", "title": "CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010564", "title": "Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281809", "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05418088", "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05442515", "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643742", "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05702853", "title": "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05705570", "title": "Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05794880", "title": "MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800210", "title": "Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05869279", "title": "Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2024-05-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05873712", "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963217", "title": "Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06037018", "title": "Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346912", "title": "CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL", "status": "RECRUITING", "last_update": "2024-05-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06355739", "title": "CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364423", "title": "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508775", "title": "Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528301", "title": "A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533579", "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06834529", "title": "CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma", "status": "RECRUITING", "last_update": "2025-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06890494", "title": "Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia", "status": "RECRUITING", "last_update": "2026-03-10", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961669", "title": "Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07194980", "title": "Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205315", "title": "A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07532525", "title": "Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143065", "title": "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00466531", "title": "Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00586391", "title": "CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00593944", "title": "Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2013-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00643240", "title": "Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2017-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709033", "title": "T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00816413", "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer", "status": "WITHDRAWN", "last_update": "2023-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00840853", "title": "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00889408", "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma", "status": "COMPLETED", "last_update": "2017-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00924326", "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01029366", "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01087294", "title": "Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01161511", "title": "Safety and Tolerability of XmAb\u00ae5574 in Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-04-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01212380", "title": "Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)", "status": "COMPLETED", "last_update": "2016-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "status": "COMPLETED", "last_update": "2017-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01416974", "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab", "status": "COMPLETED", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01466153", "title": "A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01475058", "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497184", "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01517035", "title": "Improving Blood Stem Cell Collection and Transplant Procedures", "status": "COMPLETED", "last_update": "2018-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01593696", "title": "Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma", "status": "COMPLETED", "last_update": "2020-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01626495", "title": "Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma", "status": "COMPLETED", "last_update": "2020-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01653717", "title": "CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01683279", "title": "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01747486", "title": "Dose Optimization Trial of CD19 Redirected Autologous T Cells", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01805375", "title": "A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2018-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01815749", "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864889", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005289", "title": "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007811", "title": "Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination", "status": "UNKNOWN", "last_update": "2014-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02050347", "title": "Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132624", "title": "CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.", "status": "COMPLETED", "last_update": "2017-10-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274506", "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells", "status": "WITHDRAWN", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454270", "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2018-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02456350", "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02529813", "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568553", "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640209", "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02644655", "title": "Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia", "status": "UNKNOWN", "last_update": "2016-01-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02672501", "title": "A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia", "status": "UNKNOWN", "last_update": "2016-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02685670", "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2017-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02782351", "title": "Humanized CAR-T Therapy for Treatment of B Cell Malignancy", "status": "UNKNOWN", "last_update": "2017-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02790515", "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02813837", "title": "Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2016-06-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819583", "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846584", "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848911", "title": "Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL", "status": "TERMINATED", "last_update": "2019-06-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02851589", "title": "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892695", "title": "PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02933775", "title": "CD19-redirected Autologous Cells (CAR-CD19 T Cells)", "status": "UNKNOWN", "last_update": "2016-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02935257", "title": "Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02963038", "title": "CAR T Cells for Refractory B Cell Malignancy", "status": "UNKNOWN", "last_update": "2017-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968472", "title": "A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia", "status": "UNKNOWN", "last_update": "2016-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019055", "title": "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050190", "title": "A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056339", "title": "Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03068416", "title": "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03076437", "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03085173", "title": "A Trial of \"Armored\" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03098355", "title": "Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies", "status": "WITHDRAWN", "last_update": "2024-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03110640", "title": "Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2019-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125577", "title": "Combination CAR-T Cell Therapy Targeting Hematological Malignancies", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03166878", "title": "A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2017-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185494", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191773", "title": "A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies", "status": "UNKNOWN", "last_update": "2017-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281551", "title": "Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2017-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03302403", "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors", "status": "UNKNOWN", "last_update": "2020-10-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03383952", "title": "A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia", "status": "UNKNOWN", "last_update": "2017-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03398967", "title": "A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2018-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03448393", "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463928", "title": "A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia", "status": "UNKNOWN", "last_update": "2018-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564977", "title": "CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2018-07-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03573700", "title": "Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579888", "title": "CD19-Specific T Cells Post AlloSCT", "status": "TERMINATED", "last_update": "2021-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03598179", "title": "XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects", "status": "UNKNOWN", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03599375", "title": "Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia", "status": "UNKNOWN", "last_update": "2019-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03605589", "title": "Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma", "status": "WITHDRAWN", "last_update": "2021-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03614858", "title": "CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.", "status": "UNKNOWN", "last_update": "2023-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685786", "title": "CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT", "status": "UNKNOWN", "last_update": "2018-12-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03774654", "title": "CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849651", "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853616", "title": "MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03895944", "title": "ET190L1-ARTEMIS\u2122 T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2019-03-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014894", "title": "ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2021-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016129", "title": "CAR-T Immunotherapy Targeting CD19- ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04029038", "title": "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma", "status": "WITHDRAWN", "last_update": "2023-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04100187", "title": "Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia", "status": "UNKNOWN", "last_update": "2022-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156178", "title": "CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156243", "title": "CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160195", "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2022-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260945", "title": "CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04271410", "title": "CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04271800", "title": "Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450069", "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies", "status": "COMPLETED", "last_update": "2024-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464200", "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04488354", "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04516551", "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT", "status": "UNKNOWN", "last_update": "2020-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04605666", "title": "CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies", "status": "COMPLETED", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04648475", "title": "Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04649983", "title": "CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04684563", "title": "huCART19-IL18 in CD19+ Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04714593", "title": "Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732845", "title": "Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796675", "title": "Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies", "status": "UNKNOWN", "last_update": "2021-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796688", "title": "Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies", "status": "UNKNOWN", "last_update": "2021-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2026-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020678", "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05037669", "title": "Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma", "status": "WITHDRAWN", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094206", "title": "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05236764", "title": "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259813", "title": "Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL", "status": "WITHDRAWN", "last_update": "2023-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410041", "title": "Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2022-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05487651", "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05570188", "title": "Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies", "status": "WITHDRAWN", "last_update": "2022-11-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05613348", "title": "CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma", "status": "WITHDRAWN", "last_update": "2024-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718869", "title": "Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05739227", "title": "Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2023-02-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05779930", "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05797233", "title": "Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05878184", "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932173", "title": "A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06205290", "title": "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies", "status": "WITHDRAWN", "last_update": "2024-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06343376", "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies", "status": "TERMINATED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561425", "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06662227", "title": "Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors", "status": "SUSPENDED", "last_update": "2026-05-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166419", "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166549", "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07254793", "title": "Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07412405", "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07511426", "title": "U96-CAR-T-Cells For R/R B-ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 123, "n_observational": 1, "n_active": 46, "n_withdrawn": 6, "trials": [ { "nct": "NCT01853631", "title": "Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03676504", "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR", "status": "RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04545762", "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603872", "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies", "status": "RECRUITING", "last_update": "2020-10-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892277", "title": "CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010564", "title": "Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281809", "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05418088", "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05442515", "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05702853", "title": "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05705570", "title": "Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963217", "title": "Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06346912", "title": "CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL", "status": "RECRUITING", "last_update": "2024-05-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06355739", "title": "CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364423", "title": "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06834529", "title": "CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma", "status": "RECRUITING", "last_update": "2025-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961669", "title": "Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07532525", "title": "Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00466531", "title": "Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00586391", "title": "CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709033", "title": "T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00924326", "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01029366", "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01087294", "title": "Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "status": "COMPLETED", "last_update": "2017-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01416974", "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab", "status": "COMPLETED", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01475058", "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497184", "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01626495", "title": "Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma", "status": "COMPLETED", "last_update": "2020-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01683279", "title": "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01747486", "title": "Dose Optimization Trial of CD19 Redirected Autologous T Cells", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864889", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02050347", "title": "Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132624", "title": "CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.", "status": "COMPLETED", "last_update": "2017-10-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274506", "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells", "status": "WITHDRAWN", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02456350", "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02529813", "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640209", "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02644655", "title": "Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia", "status": "UNKNOWN", "last_update": "2016-01-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02672501", "title": "A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia", "status": "UNKNOWN", "last_update": "2016-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02685670", "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2017-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02782351", "title": "Humanized CAR-T Therapy for Treatment of B Cell Malignancy", "status": "UNKNOWN", "last_update": "2017-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02790515", "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02813837", "title": "Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2016-06-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819583", "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846584", "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02933775", "title": "CD19-redirected Autologous Cells (CAR-CD19 T Cells)", "status": "UNKNOWN", "last_update": "2016-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02935257", "title": "Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02963038", "title": "CAR T Cells for Refractory B Cell Malignancy", "status": "UNKNOWN", "last_update": "2017-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019055", "title": "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056339", "title": "Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03068416", "title": "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03076437", "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03085173", "title": "A Trial of \"Armored\" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03098355", "title": "Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies", "status": "WITHDRAWN", "last_update": "2024-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03110640", "title": "Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2019-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125577", "title": "Combination CAR-T Cell Therapy Targeting Hematological Malignancies", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03166878", "title": "A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2017-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185494", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191773", "title": "A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies", "status": "UNKNOWN", "last_update": "2017-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03302403", "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors", "status": "UNKNOWN", "last_update": "2020-10-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03383952", "title": "A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia", "status": "UNKNOWN", "last_update": "2017-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03398967", "title": "A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2018-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03448393", "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463928", "title": "A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia", "status": "UNKNOWN", "last_update": "2018-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564977", "title": "CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2018-07-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03573700", "title": "Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579888", "title": "CD19-Specific T Cells Post AlloSCT", "status": "TERMINATED", "last_update": "2021-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03598179", "title": "XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects", "status": "UNKNOWN", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03599375", "title": "Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia", "status": "UNKNOWN", "last_update": "2019-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03614858", "title": "CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.", "status": "UNKNOWN", "last_update": "2023-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685786", "title": "CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT", "status": "UNKNOWN", "last_update": "2018-12-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03774654", "title": "CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849651", "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853616", "title": "MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03895944", "title": "ET190L1-ARTEMIS\u2122 T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2019-03-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014894", "title": "ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2021-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016129", "title": "CAR-T Immunotherapy Targeting CD19- ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04029038", "title": "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma", "status": "WITHDRAWN", "last_update": "2023-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04100187", "title": "Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia", "status": "UNKNOWN", "last_update": "2022-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156178", "title": "CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156243", "title": "CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160195", "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2022-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260945", "title": "CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04271410", "title": "CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04271800", "title": "Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464200", "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04488354", "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04516551", "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT", "status": "UNKNOWN", "last_update": "2020-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04605666", "title": "CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies", "status": "COMPLETED", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04648475", "title": "Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04649983", "title": "CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04684563", "title": "huCART19-IL18 in CD19+ Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04714593", "title": "Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732845", "title": "Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796675", "title": "Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies", "status": "UNKNOWN", "last_update": "2021-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796688", "title": "Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies", "status": "UNKNOWN", "last_update": "2021-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020678", "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05037669", "title": "Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma", "status": "WITHDRAWN", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094206", "title": "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05236764", "title": "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410041", "title": "Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies", "status": "UNKNOWN", "last_update": "2022-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05487651", "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05570188", "title": "Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies", "status": "WITHDRAWN", "last_update": "2022-11-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05613348", "title": "CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma", "status": "WITHDRAWN", "last_update": "2024-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05739227", "title": "Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2023-02-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05779930", "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05797233", "title": "Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932173", "title": "A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06343376", "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies", "status": "TERMINATED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06662227", "title": "Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors", "status": "SUSPENDED", "last_update": "2026-05-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166419", "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166549", "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07412405", "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07511426", "title": "U96-CAR-T-Cells For R/R B-ALL", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD19", "lisocabtagene", "liso-cel", "Breyanzi" ] }, "ROR1": { "n": 10, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT02194374", "title": "Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)", "status": "WITHDRAWN", "last_update": "2017-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02222688", "title": "UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "status": "TERMINATED", "last_update": "2022-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02860676", "title": "Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088878", "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833180", "title": "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)", "status": "COMPLETED", "last_update": "2024-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04501939", "title": "Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04763083", "title": "First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies", "status": "UNKNOWN", "last_update": "2023-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05458297", "title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02194374", "title": "Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)", "status": "WITHDRAWN", "last_update": "2017-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "status": "TERMINATED", "last_update": "2022-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "ROR1", "zilovertamab", "cirmtuzumab" ] }, "CD52": { "n": 77, "n_observational": 4, "n_active": 2, "n_withdrawn": 2, "trials": [ { "nct": "NCT00004857", "title": "Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006390", "title": "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00021151", "title": "Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00027560", "title": "Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "COMPLETED", "last_update": "2013-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038883", "title": "Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2018-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00040846", "title": "Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00046683", "title": "Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00056966", "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases", "status": "COMPLETED", "last_update": "2012-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071396", "title": "Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00074282", "title": "Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085449", "title": "Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "WITHDRAWN", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086580", "title": "Fludarabine (Fludara\u00ae) Plus Alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086775", "title": "Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098670", "title": "Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00102661", "title": "Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104975", "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "status": "COMPLETED", "last_update": "2016-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00109993", "title": "Campath-1H + FK506 and Methylprednisolone for GVHD", "status": "COMPLETED", "last_update": "2010-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118352", "title": "Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "status": "COMPLETED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143065", "title": "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00147901", "title": "Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)", "status": "COMPLETED", "last_update": "2016-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00162851", "title": "Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2007-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193466", "title": "Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2010-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206726", "title": "Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)", "status": "COMPLETED", "last_update": "2016-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00230282", "title": "Phase 2 Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274976", "title": "Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00276809", "title": "Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278213", "title": "Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281983", "title": "Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2017-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00292760", "title": "A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion", "status": "COMPLETED", "last_update": "2009-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00328198", "title": "Subcutaneous Alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330252", "title": "Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00336206", "title": "Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2006-07-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337519", "title": "Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2009-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349349", "title": "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab", "status": "COMPLETED", "last_update": "2014-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354120", "title": "Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00368355", "title": "T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts", "status": "COMPLETED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410657", "title": "Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2010-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00436904", "title": "Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2011-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "status": "COMPLETED", "last_update": "2017-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00458523", "title": "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission", "status": "COMPLETED", "last_update": "2013-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462332", "title": "Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00504491", "title": "R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2011-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525603", "title": "CFAR Study in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555048", "title": "Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "TERMINATED", "last_update": "2017-05-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562328", "title": "Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562770", "title": "Oral Valganciclovir Versus Valacyclovir", "status": "COMPLETED", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00564512", "title": "Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP", "status": "COMPLETED", "last_update": "2013-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00565981", "title": "A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response", "status": "COMPLETED", "last_update": "2017-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00566696", "title": "Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies", "status": "COMPLETED", "last_update": "2020-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00579111", "title": "Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)", "status": "TERMINATED", "last_update": "2016-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00587847", "title": "Campath Maintenance in Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2015-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634881", "title": "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00669318", "title": "Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2014-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00683046", "title": "T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2016-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698685", "title": "Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "status": "TERMINATED", "last_update": "2015-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00800943", "title": "Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy", "status": "UNKNOWN", "last_update": "2008-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00858117", "title": "A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871546", "title": "SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)", "status": "TERMINATED", "last_update": "2015-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923182", "title": "A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00935792", "title": "Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00947388", "title": "Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2013-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00951457", "title": "Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013441", "title": "CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013961", "title": "Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01082939", "title": "Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2012-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191749", "title": "Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)", "status": "TERMINATED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361711", "title": "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01392079", "title": "Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine", "status": "COMPLETED", "last_update": "2019-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01982175", "title": "Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia", "status": "SUSPENDED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701517", "title": "Cyclosporine Plus Methotrexate or Alemtuzumab", "status": "TERMINATED", "last_update": "2017-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04312841", "title": "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00104975", "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "status": "COMPLETED", "last_update": "2016-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013441", "title": "CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD52", "alemtuzumab" ] }, "BTK": { "n": 297, "n_observational": 49, "n_active": 159, "n_withdrawn": 16, "trials": [ { "nct": "NCT01804686", "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516617", "title": "Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980002", "title": "A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL", "status": "RECRUITING", "last_update": "2019-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494503", "title": "Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL", "status": "RECRUITING", "last_update": "2025-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04502394", "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL", "status": "RECRUITING", "last_update": "2022-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523428", "title": "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771507", "title": "A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2021-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908228", "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-na\u00efve Patients With CLL", "status": "RECRUITING", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941716", "title": "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05006716", "title": "A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05131022", "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168930", "title": "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05254743", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05294731", "title": "Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388006", "title": "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05602363", "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2025-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643235", "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694312", "title": "Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL", "status": "RECRUITING", "last_update": "2023-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05780034", "title": "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05873712", "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950997", "title": "A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL", "status": "RECRUITING", "last_update": "2024-05-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043674", "title": "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06104566", "title": "Global Trial in APG2575 for Patients With CLL/SLL", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136559", "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06319456", "title": "A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333262", "title": "Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06466122", "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544785", "title": "Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06588478", "title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06697184", "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735664", "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation", "status": "RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757647", "title": "Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06812715", "title": "Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839053", "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06846671", "title": "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06863402", "title": "Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06876649", "title": "A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06876662", "title": "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973187", "title": "A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06978088", "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014917", "title": "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07194980", "title": "Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218341", "title": "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07221500", "title": "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271667", "title": "A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07321652", "title": "Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07342478", "title": "ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428707", "title": "Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07516093", "title": "Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07609862", "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671378", "title": "A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Na\u00efve, High-Risk CLL/SLL Patients", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685717", "title": "Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07734038", "title": "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849654", "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01105247", "title": "Safety of PCI-32765 in Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109069", "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217749", "title": "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292135", "title": "Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01351935", "title": "Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2019-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01500733", "title": "PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520519", "title": "Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01589302", "title": "PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01611090", "title": "A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "status": "TERMINATED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01722487", "title": "Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL", "status": "COMPLETED", "last_update": "2017-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01724346", "title": "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744691", "title": "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion", "status": "COMPLETED", "last_update": "2017-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01752426", "title": "Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL", "status": "COMPLETED", "last_update": "2020-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01799889", "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies", "status": "TERMINATED", "last_update": "2020-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01886859", "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2022-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01886872", "title": "Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973387", "title": "A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma", "status": "COMPLETED", "last_update": "2018-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005289", "title": "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006485", "title": "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies", "status": "COMPLETED", "last_update": "2019-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007044", "title": "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013128", "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029443", "title": "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02048813", "title": "Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "status": "TERMINATED", "last_update": "2015-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141282", "title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02157324", "title": "Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02160015", "title": "Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02200848", "title": "Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2018-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02232386", "title": "Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02251548", "title": "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264574", "title": "A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na\u00efve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02268851", "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02292225", "title": "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)", "status": "TERMINATED", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02301156", "title": "Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02303392", "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315768", "title": "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02337829", "title": "Acalabrutinib in Patients With Relapsed/Refractory and Treatment na\u00efve Deletion 17p CLL/SLL", "status": "COMPLETED", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352558", "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02362035", "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381080", "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy", "status": "COMPLETED", "last_update": "2017-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02388048", "title": "Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02420912", "title": "Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation", "status": "COMPLETED", "last_update": "2024-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475681", "title": "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02477696", "title": "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514083", "title": "A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02518555", "title": "Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537613", "title": "A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02556892", "title": "A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02557516", "title": "Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586857", "title": "A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611908", "title": "Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.", "status": "WITHDRAWN", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614508", "title": "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629809", "title": "Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640209", "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649387", "title": "Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy", "status": "COMPLETED", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662296", "title": "Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2017-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02666898", "title": "Phase II Trial GA101 Inbrutinib B CLL", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02677948", "title": "Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "WITHDRAWN", "last_update": "2017-09-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689141", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)", "status": "COMPLETED", "last_update": "2020-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02717611", "title": "A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02742090", "title": "Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy", "status": "TERMINATED", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743546", "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma", "status": "WITHDRAWN", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756897", "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757040", "title": "Combination of Ibrutinib and As2O3 in the Treatment of CLL", "status": "UNKNOWN", "last_update": "2016-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02759016", "title": "Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02787369", "title": "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02801578", "title": "A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-02-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02863718", "title": "Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869633", "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02891590", "title": "Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2020-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02900716", "title": "Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas", "status": "COMPLETED", "last_update": "2020-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02910583", "title": "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02912754", "title": "Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients", "status": "UNKNOWN", "last_update": "2017-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914327", "title": "Safety and Activity of SNX-5422 Plus Ibrutinib in CLL", "status": "WITHDRAWN", "last_update": "2018-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914938", "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2023-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02970318", "title": "A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973399", "title": "Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL", "status": "TERMINATED", "last_update": "2019-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02991638", "title": "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers", "status": "UNKNOWN", "last_update": "2018-04-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03037645", "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers", "status": "TERMINATED", "last_update": "2020-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045328", "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088878", "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153202", "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190330", "title": "A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion", "status": "COMPLETED", "last_update": "2025-05-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03204188", "title": "Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03206918", "title": "Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207555", "title": "Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226301", "title": "A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations", "status": "UNKNOWN", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03229200", "title": "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03265717", "title": "DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2020-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267186", "title": "Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant", "status": "COMPLETED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280160", "title": "Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab", "status": "UNKNOWN", "last_update": "2022-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03301207", "title": "A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy", "status": "COMPLETED", "last_update": "2019-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03328273", "title": "A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03370185", "title": "Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03400176", "title": "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib", "status": "TERMINATED", "last_update": "2025-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447808", "title": "Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03454165", "title": "A Study of BNC105P Combined With Ibrutinib", "status": "COMPLETED", "last_update": "2023-01-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03479268", "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513562", "title": "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514017", "title": "Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03572634", "title": "Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671590", "title": "Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies", "status": "TERMINATED", "last_update": "2024-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685708", "title": "HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03702231", "title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708003", "title": "Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734016", "title": "A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734198", "title": "Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03771157", "title": "Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03788291", "title": "Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884972", "title": "Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor", "status": "WITHDRAWN", "last_update": "2023-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03899337", "title": "A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03932331", "title": "Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03943342", "title": "Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03960840", "title": "Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04008706", "title": "Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04043845", "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075292", "title": "Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116437", "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155710", "title": "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL", "status": "COMPLETED", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172246", "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04178798", "title": "Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04189952", "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209621", "title": "Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230304", "title": "Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282018", "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab", "status": "COMPLETED", "last_update": "2026-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305444", "title": "Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas", "status": "TERMINATED", "last_update": "2025-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419389", "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458610", "title": "Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04505254", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04657094", "title": "Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660045", "title": "Early Intervention With Acalabrutinib in Patients With High Risk CLL", "status": "WITHDRAWN", "last_update": "2022-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665115", "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)", "status": "WITHDRAWN", "last_update": "2022-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685915", "title": "Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL", "status": "WITHDRAWN", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04688385", "title": "Personalized Multi-peptide Vaccination in CLL Patients", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716075", "title": "Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722172", "title": "A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04754035", "title": "Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04781855", "title": "Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation", "status": "WITHDRAWN", "last_update": "2025-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849416", "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04876092", "title": "A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04883749", "title": "Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-na\u00efve or Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04930536", "title": "Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963946", "title": "STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965493", "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992377", "title": "R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL", "status": "UNKNOWN", "last_update": "2021-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05023980", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024045", "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers", "status": "COMPLETED", "last_update": "2026-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176691", "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL", "status": "WITHDRAWN", "last_update": "2023-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287984", "title": "Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL", "status": "UNKNOWN", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317936", "title": "Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax", "status": "TERMINATED", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365100", "title": "A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL", "status": "WITHDRAWN", "last_update": "2023-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677919", "title": "Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718869", "title": "Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963074", "title": "A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05971251", "title": "Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367374", "title": "MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547944", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06637501", "title": "A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788509", "title": "A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839872", "title": "A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06970743", "title": "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003464", "title": "Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162181", "title": "Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508995", "title": "A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07526597", "title": "Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07557056", "title": "Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07592481", "title": "Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624799", "title": "Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674810", "title": "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07682415", "title": "Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL\uff1aStop Trial 2.0", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738887", "title": "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739459", "title": "Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796373", "title": "Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07812246", "title": "Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640209", "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155710", "title": "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL", "status": "COMPLETED", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "BTK", "ibrutinib", "acalabrutinib", "zanubrutinib", "pirtobrutinib" ] }, "BCL-2": { "n": 171, "n_observational": 25, "n_active": 95, "n_withdrawn": 7, "trials": [ { "nct": "NCT03986034", "title": "Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04269902", "title": "Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523428", "title": "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588922", "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895436", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941716", "title": "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091424", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05131022", "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168930", "title": "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183854", "title": "Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388006", "title": "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791409", "title": "Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL", "status": "RECRUITING", "last_update": "2024-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05947851", "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06466122", "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644183", "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839053", "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06846671", "title": "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06978088", "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014917", "title": "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154264", "title": "A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218510", "title": "Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07221500", "title": "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07342478", "title": "ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07520006", "title": "Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07609823", "title": "A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07609862", "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07734038", "title": "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00021749", "title": "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2009-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00024440", "title": "Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00054639", "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060112", "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma", "status": "TERMINATED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078234", "title": "Genasense\u00ae (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2011-11-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00285103", "title": "SPC2996 in Chronic Lymphocytic Leukaemia", "status": "COMPLETED", "last_update": "2011-02-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00612612", "title": "Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "status": "TERMINATED", "last_update": "2014-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01087151", "title": "A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01328626", "title": "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2022-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671904", "title": "A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682616", "title": "A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685892", "title": "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "status": "COMPLETED", "last_update": "2021-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005471", "title": "A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141282", "title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242942", "title": "Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02265731", "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640833", "title": "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor", "status": "WITHDRAWN", "last_update": "2016-07-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756611", "title": "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2023-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756897", "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846623", "title": "Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02910583", "title": "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02920697", "title": "Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02966756", "title": "A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980731", "title": "A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).", "status": "COMPLETED", "last_update": "2023-02-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045328", "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226301", "title": "A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations", "status": "UNKNOWN", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03343678", "title": "This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax", "status": "WITHDRAWN", "last_update": "2018-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455517", "title": "Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03467867", "title": "A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513562", "title": "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534323", "title": "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03547115", "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML", "status": "TERMINATED", "last_update": "2026-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03572634", "title": "Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576547", "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609593", "title": "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639324", "title": "Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL", "status": "WITHDRAWN", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708003", "title": "Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739554", "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755154", "title": "Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766763", "title": "Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "status": "TERMINATED", "last_update": "2024-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844048", "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884972", "title": "Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor", "status": "WITHDRAWN", "last_update": "2023-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913949", "title": "A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03943342", "title": "Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04149821", "title": "Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy", "status": "TERMINATED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285567", "title": "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356846", "title": "A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419389", "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419519", "title": "Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447768", "title": "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04501939", "title": "Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512105", "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "status": "TERMINATED", "last_update": "2025-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04682808", "title": "A Study of FCN-338 in Patients With Chronic CLL/SLL", "status": "UNKNOWN", "last_update": "2024-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04754035", "title": "Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04790045", "title": "Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04843904", "title": "Safe Accelerated Venetoclax Escalation in CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965493", "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04981912", "title": "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024045", "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers", "status": "COMPLETED", "last_update": "2026-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069051", "title": "Belimumab in Patients with Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209308", "title": "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL", "status": "WITHDRAWN", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317936", "title": "Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax", "status": "TERMINATED", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433532", "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05479994", "title": "Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677919", "title": "Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "status": "TERMINATED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05959694", "title": "A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .", "status": "UNKNOWN", "last_update": "2023-10-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963074", "title": "A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07082452", "title": "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Na\u00efve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508995", "title": "A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07557056", "title": "Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690891", "title": "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07691047", "title": "Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738887", "title": "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07753369", "title": "A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796373", "title": "Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07812246", "title": "Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "BCL-2", "BCL2", "venetoclax", "Venclexta" ] } }, "by_drug": { "ACALABRUTINIB": { "n": 73, "n_observational": 17, "n_active": 50, "n_withdrawn": 3, "trials": [ { "nct": "NCT03516617", "title": "Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04502394", "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL", "status": "RECRUITING", "last_update": "2022-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523428", "title": "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941716", "title": "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388006", "title": "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643235", "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950997", "title": "A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL", "status": "RECRUITING", "last_update": "2024-05-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136559", "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06319456", "title": "A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757647", "title": "Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014917", "title": "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029443", "title": "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02157324", "title": "Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02337829", "title": "Acalabrutinib in Patients With Relapsed/Refractory and Treatment na\u00efve Deletion 17p CLL/SLL", "status": "COMPLETED", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02362035", "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475681", "title": "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02477696", "title": "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586857", "title": "A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02717611", "title": "A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02970318", "title": "A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03328273", "title": "A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685708", "title": "HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03702231", "title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03788291", "title": "Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03899337", "title": "A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03932331", "title": "Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04008706", "title": "Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075292", "title": "Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116437", "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155710", "title": "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL", "status": "COMPLETED", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04178798", "title": "Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04189952", "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419389", "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04505254", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04657094", "title": "Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660045", "title": "Early Intervention With Acalabrutinib in Patients With High Risk CLL", "status": "WITHDRAWN", "last_update": "2022-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685915", "title": "Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL", "status": "WITHDRAWN", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716075", "title": "Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722172", "title": "A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04883749", "title": "Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-na\u00efve or Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04930536", "title": "Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963946", "title": "STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05971251", "title": "Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839872", "title": "A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALEMTUZUMAB": { "n": 77, "n_observational": 4, "n_active": 2, "n_withdrawn": 2, "trials": [ { "nct": "NCT00004857", "title": "Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006390", "title": "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00021151", "title": "Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00027560", "title": "Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "COMPLETED", "last_update": "2013-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038883", "title": "Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2018-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00040846", "title": "Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00046683", "title": "Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00056966", "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases", "status": "COMPLETED", "last_update": "2012-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071396", "title": "Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00074282", "title": "Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085449", "title": "Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "WITHDRAWN", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086580", "title": "Fludarabine (Fludara\u00ae) Plus Alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086775", "title": "Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098670", "title": "Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00102661", "title": "Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104975", "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "status": "COMPLETED", "last_update": "2016-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00109993", "title": "Campath-1H + FK506 and Methylprednisolone for GVHD", "status": "COMPLETED", "last_update": "2010-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118352", "title": "Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "status": "COMPLETED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143065", "title": "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00147901", "title": "Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)", "status": "COMPLETED", "last_update": "2016-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00162851", "title": "Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2007-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193466", "title": "Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2010-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206726", "title": "Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)", "status": "COMPLETED", "last_update": "2016-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00230282", "title": "Phase 2 Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274976", "title": "Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00276809", "title": "Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278213", "title": "Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281983", "title": "Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2017-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00292760", "title": "A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion", "status": "COMPLETED", "last_update": "2009-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00328198", "title": "Subcutaneous Alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330252", "title": "Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00336206", "title": "Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2006-07-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337519", "title": "Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2009-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349349", "title": "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab", "status": "COMPLETED", "last_update": "2014-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354120", "title": "Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00368355", "title": "T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts", "status": "COMPLETED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410657", "title": "Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2010-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00436904", "title": "Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2011-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "status": "COMPLETED", "last_update": "2017-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00458523", "title": "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission", "status": "COMPLETED", "last_update": "2013-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462332", "title": "Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00504491", "title": "R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2011-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525603", "title": "CFAR Study in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555048", "title": "Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer", "status": "TERMINATED", "last_update": "2017-05-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562328", "title": "Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562770", "title": "Oral Valganciclovir Versus Valacyclovir", "status": "COMPLETED", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00564512", "title": "Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP", "status": "COMPLETED", "last_update": "2013-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00565981", "title": "A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response", "status": "COMPLETED", "last_update": "2017-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00566696", "title": "Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies", "status": "COMPLETED", "last_update": "2020-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00579111", "title": "Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)", "status": "TERMINATED", "last_update": "2016-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00587847", "title": "Campath Maintenance in Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2015-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634881", "title": "Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00669318", "title": "Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2014-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00683046", "title": "T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2016-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698685", "title": "Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "status": "TERMINATED", "last_update": "2015-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00800943", "title": "Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy", "status": "UNKNOWN", "last_update": "2008-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00858117", "title": "A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL", "status": "COMPLETED", "last_update": "2020-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871546", "title": "SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)", "status": "TERMINATED", "last_update": "2015-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923182", "title": "A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00935792", "title": "Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00947388", "title": "Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2013-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00951457", "title": "Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013441", "title": "CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013961", "title": "Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01082939", "title": "Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2012-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191749", "title": "Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)", "status": "TERMINATED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361711", "title": "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01392079", "title": "Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine", "status": "COMPLETED", "last_update": "2019-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01982175", "title": "Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia", "status": "SUSPENDED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701517", "title": "Cyclosporine Plus Methotrexate or Alemtuzumab", "status": "TERMINATED", "last_update": "2017-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04312841", "title": "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416984", "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALEMTUZUMAB BETA": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMG-319": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01300026", "title": "AMG 319 Lymphoid Malignancy FIH", "status": "COMPLETED", "last_update": "2017-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "APG-2575": { "n": 6, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04215809", "title": "Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL", "status": "RECRUITING", "last_update": "2025-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494503", "title": "Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL", "status": "RECRUITING", "last_update": "2025-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05147467", "title": "Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06104566", "title": "Global Trial in APG2575 for Patients With CLL/SLL", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06319456", "title": "A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913949", "title": "A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BLINATUMOMAB": { "n": 10, "n_observational": 1, "n_active": 6, "n_withdrawn": 2, "trials": [ { "nct": "NCT03263572", "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03595917", "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260022", "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL", "status": "RECRUITING", "last_update": "2025-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00676871", "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)", "status": "WITHDRAWN", "last_update": "2008-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568553", "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02790515", "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03605589", "title": "Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma", "status": "WITHDRAWN", "last_update": "2021-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823365", "title": "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849651", "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BREXUCABTAGENE AUTOLEUCEL": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02340780", "title": "Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614508", "title": "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CENERSEN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00636155", "title": "EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2012-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CIRMTUZUMAB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02222688", "title": "UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02860676", "title": "Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088878", "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04501939", "title": "Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884998", "title": "Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155840", "title": "Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685915", "title": "Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL", "status": "WITHDRAWN", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DACTOLISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01756118", "title": "A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2023-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DUVELISIB": { "n": 13, "n_observational": 2, "n_active": 3, "n_withdrawn": 3, "trials": [ { "nct": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "status": "COMPLETED", "last_update": "2016-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004522", "title": "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049515", "title": "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158091", "title": "A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02292225", "title": "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)", "status": "TERMINATED", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576275", "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)", "status": "WITHDRAWN", "last_update": "2021-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640833", "title": "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor", "status": "WITHDRAWN", "last_update": "2016-07-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03370185", "title": "Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534323", "title": "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03757000", "title": "A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2018-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03892044", "title": "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-05-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03961672", "title": "Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209621", "title": "Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPCORITAMAB": { "n": 9, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT05791409", "title": "Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL", "status": "RECRUITING", "last_update": "2024-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07108998", "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218510", "title": "Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03625037", "title": "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358458", "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2024-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542824", "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676033", "title": "Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738887", "title": "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04419389", "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FENEBRUTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01991184", "title": "A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "GLOFITAMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06043674", "title": "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IBRUTINIB": { "n": 151, "n_observational": 27, "n_active": 52, "n_withdrawn": 10, "trials": [ { "nct": "NCT01804686", "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980002", "title": "A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL", "status": "RECRUITING", "last_update": "2019-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494503", "title": "Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL", "status": "RECRUITING", "last_update": "2025-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771507", "title": "A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2021-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908228", "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-na\u00efve Patients With CLL", "status": "RECRUITING", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05254743", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643235", "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694312", "title": "Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL", "status": "RECRUITING", "last_update": "2023-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136559", "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757647", "title": "Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849654", "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01105247", "title": "Safety of PCI-32765 in Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109069", "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217749", "title": "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292135", "title": "Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01500733", "title": "PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520519", "title": "Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01589302", "title": "PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01611090", "title": "A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "status": "TERMINATED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01722487", "title": "Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL", "status": "COMPLETED", "last_update": "2017-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01724346", "title": "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744691", "title": "A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion", "status": "COMPLETED", "last_update": "2017-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01752426", "title": "Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL", "status": "COMPLETED", "last_update": "2020-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01886859", "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2022-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01886872", "title": "Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973387", "title": "A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma", "status": "COMPLETED", "last_update": "2018-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005289", "title": "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006485", "title": "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies", "status": "COMPLETED", "last_update": "2019-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007044", "title": "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013128", "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029443", "title": "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02048813", "title": "Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "status": "TERMINATED", "last_update": "2015-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141282", "title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02160015", "title": "Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02200848", "title": "Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2018-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02232386", "title": "Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02251548", "title": "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264574", "title": "A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na\u00efve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02268851", "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02301156", "title": "Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02303392", "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315768", "title": "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352558", "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381080", "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy", "status": "COMPLETED", "last_update": "2017-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02388048", "title": "Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02420912", "title": "Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation", "status": "COMPLETED", "last_update": "2024-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02477696", "title": "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514083", "title": "A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02518555", "title": "Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537613", "title": "A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02556892", "title": "A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02557516", "title": "Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611908", "title": "Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.", "status": "WITHDRAWN", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614508", "title": "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629809", "title": "Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640209", "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649387", "title": "Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy", "status": "COMPLETED", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662296", "title": "Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2017-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02666898", "title": "Phase II Trial GA101 Inbrutinib B CLL", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02677948", "title": "Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "WITHDRAWN", "last_update": "2017-09-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689141", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)", "status": "COMPLETED", "last_update": "2020-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02717611", "title": "A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743546", "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma", "status": "WITHDRAWN", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756897", "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757040", "title": "Combination of Ibrutinib and As2O3 in the Treatment of CLL", "status": "UNKNOWN", "last_update": "2016-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02759016", "title": "Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02787369", "title": "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02801578", "title": "A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-02-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02863718", "title": "Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869633", "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02910583", "title": "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02912754", "title": "Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients", "status": "UNKNOWN", "last_update": "2017-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914327", "title": "Safety and Activity of SNX-5422 Plus Ibrutinib in CLL", "status": "WITHDRAWN", "last_update": "2018-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973399", "title": "Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL", "status": "TERMINATED", "last_update": "2019-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02991638", "title": "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers", "status": "UNKNOWN", "last_update": "2018-04-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045328", "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088878", "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153202", "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190330", "title": "A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion", "status": "COMPLETED", "last_update": "2025-05-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03204188", "title": "Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207555", "title": "Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226301", "title": "A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations", "status": "UNKNOWN", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03229200", "title": "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03265717", "title": "DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2020-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267186", "title": "Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant", "status": "COMPLETED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280160", "title": "Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab", "status": "UNKNOWN", "last_update": "2022-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03301207", "title": "A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy", "status": "COMPLETED", "last_update": "2019-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03400176", "title": "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib", "status": "TERMINATED", "last_update": "2025-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447808", "title": "Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03454165", "title": "A Study of BNC105P Combined With Ibrutinib", "status": "COMPLETED", "last_update": "2023-01-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03479268", "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513562", "title": "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514017", "title": "Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03572634", "title": "Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685708", "title": "HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03702231", "title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708003", "title": "Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734016", "title": "A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734198", "title": "Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03943342", "title": "Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03960840", "title": "Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04008706", "title": "Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04043845", "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116437", "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155710", "title": "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL", "status": "COMPLETED", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209621", "title": "Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230304", "title": "Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665115", "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)", "status": "WITHDRAWN", "last_update": "2022-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685915", "title": "Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL", "status": "WITHDRAWN", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04688385", "title": "Personalized Multi-peptide Vaccination in CLL Patients", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04754035", "title": "Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04781855", "title": "Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation", "status": "WITHDRAWN", "last_update": "2025-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04876092", "title": "A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992377", "title": "R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL", "status": "UNKNOWN", "last_update": "2021-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963074", "title": "A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788509", "title": "A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738887", "title": "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDELALISIB": { "n": 41, "n_observational": 6, "n_active": 6, "n_withdrawn": 4, "trials": [ { "nct": "NCT06846671", "title": "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139873", "title": "A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218341", "title": "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00710528", "title": "Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090414", "title": "An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study", "status": "TERMINATED", "last_update": "2019-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01203930", "title": "A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01282424", "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2019-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306643", "title": "Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma", "status": "COMPLETED", "last_update": "2018-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01539291", "title": "Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)", "status": "TERMINATED", "last_update": "2019-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01539512", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01569295", "title": "Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )", "status": "COMPLETED", "last_update": "2020-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "status": "TERMINATED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659021", "title": "Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659047", "title": "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2012-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732913", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732926", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01796470", "title": "Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies", "status": "TERMINATED", "last_update": "2020-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980875", "title": "Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980888", "title": "Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02044822", "title": "Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135133", "title": "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141282", "title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242045", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538614", "title": "Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2020-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662296", "title": "Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2017-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02787369", "title": "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968563", "title": "Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02970318", "title": "A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03133221", "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03151057", "title": "Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639324", "title": "Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL", "status": "WITHDRAWN", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03757000", "title": "A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2018-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06205290", "title": "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies", "status": "WITHDRAWN", "last_update": "2024-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "INEBILIZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01466153", "title": "A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LFB-R603": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01098188", "title": "LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2012-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LISOCABTAGENE MARALEUCEL": { "n": 5, "n_observational": 2, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT05873712", "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07194980", "title": "Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06205290", "title": "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies", "status": "WITHDRAWN", "last_update": "2024-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "LONCASTUXIMAB TESIRINE": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669017", "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05971251", "title": "Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MDX-1342": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00593944", "title": "Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2013-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MOSUNETUZUMAB": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05091424", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07566364", "title": "Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500407", "title": "A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MT-3724": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02361346", "title": "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02556346", "title": "Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2016-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAVITOCLAX": { "n": 10, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00406809", "title": "A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00481091", "title": "A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00743028", "title": "Assess the Oral Bioavailability of New ABT-263 Formulations", "status": "COMPLETED", "last_update": "2010-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00788684", "title": "Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers", "status": "COMPLETED", "last_update": "2025-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00868413", "title": "Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00918450", "title": "Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen", "status": "WITHDRAWN", "last_update": "2010-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01021358", "title": "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).", "status": "COMPLETED", "last_update": "2010-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01087151", "title": "A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121133", "title": "A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax", "status": "COMPLETED", "last_update": "2017-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01557777", "title": "Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04502394", "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL", "status": "RECRUITING", "last_update": "2022-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02825836", "title": "Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Na\u00efve and R/R CLL/SLL Subjects", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OBATOCLAX": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00438178", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00538187", "title": "Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2015-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00600964", "title": "A Phase I/II Study of GX15-070MS in Untreated CLL", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00612612", "title": "Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "status": "TERMINATED", "last_update": "2014-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OBINUTUZUMAB": { "n": 102, "n_observational": 10, "n_active": 54, "n_withdrawn": 2, "trials": [ { "nct": "NCT03516617", "title": "Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04269902", "title": "Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895436", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908228", "title": "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-na\u00efve Patients With CLL", "status": "RECRUITING", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950997", "title": "A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL", "status": "RECRUITING", "last_update": "2024-05-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043674", "title": "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333262", "title": "Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544785", "title": "Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762431", "title": "Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06916767", "title": "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06978088", "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07108998", "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218510", "title": "Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07520006", "title": "Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010061", "title": "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300247", "title": "A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)", "status": "COMPLETED", "last_update": "2017-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01414205", "title": "A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)", "status": "COMPLETED", "last_update": "2017-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "status": "TERMINATED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671904", "title": "A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01680991", "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease", "status": "COMPLETED", "last_update": "2016-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685892", "title": "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01868893", "title": "An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905943", "title": "A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-10-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980875", "title": "Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01998880", "title": "CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02053610", "title": "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02071225", "title": "A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02100852", "title": "TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02225275", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02229422", "title": "A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)", "status": "UNKNOWN", "last_update": "2023-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242942", "title": "Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264574", "title": "A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na\u00efve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02292225", "title": "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)", "status": "TERMINATED", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02315768", "title": "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320487", "title": "A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336048", "title": "A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities", "status": "TERMINATED", "last_update": "2021-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02371590", "title": "Lenalidomide and Obinutuzumab for Previously Untreated CLL", "status": "WITHDRAWN", "last_update": "2018-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475681", "title": "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na\u00efve CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537613", "title": "A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611908", "title": "Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.", "status": "WITHDRAWN", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02612311", "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629809", "title": "Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02666898", "title": "Phase II Trial GA101 Inbrutinib B CLL", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846623", "title": "Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968563", "title": "Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983617", "title": "Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010358", "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153514", "title": "Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2022-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03759184", "title": "Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia", "status": "TERMINATED", "last_update": "2022-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059081", "title": "A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment", "status": "UNKNOWN", "last_update": "2019-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245722", "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies", "status": "TERMINATED", "last_update": "2023-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285567", "title": "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434196", "title": "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447768", "title": "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04505254", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578600", "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722172", "title": "A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04843904", "title": "Safe Accelerated Venetoclax Escalation in CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322733", "title": "Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL", "status": "UNKNOWN", "last_update": "2022-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06291220", "title": "A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547944", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06970743", "title": "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003464", "title": "Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624799", "title": "Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674810", "title": "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690891", "title": "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OBLIMERSEN": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00021749", "title": "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2009-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00024440", "title": "Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00054639", "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060112", "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma", "status": "TERMINATED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078234", "title": "Genasense\u00ae (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2011-11-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517218", "title": "This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)", "status": "WITHDRAWN", "last_update": "2008-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "OCARATUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ODRONEXTAMAB": { "n": 2, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06735664", "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation", "status": "RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OFATUMUMAB": { "n": 58, "n_observational": 1, "n_active": 1, "n_withdrawn": 3, "trials": [ { "nct": "NCT00093314", "title": "HuMax-CD20 in Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2015-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349349", "title": "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab", "status": "COMPLETED", "last_update": "2014-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410163", "title": "Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients", "status": "COMPLETED", "last_update": "2014-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00742144", "title": "Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00748189", "title": "Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00802737", "title": "Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-05-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00824265", "title": "Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01002755", "title": "Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010568", "title": "Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01024010", "title": "Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2018-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039376", "title": "Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy", "status": "TERMINATED", "last_update": "2019-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077622", "title": "A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01110031", "title": "Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01113632", "title": "Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2016-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01119794", "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab", "status": "TERMINATED", "last_update": "2015-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123356", "title": "Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab", "status": "COMPLETED", "last_update": "2015-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125787", "title": "Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab", "status": "TERMINATED", "last_update": "2011-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01131247", "title": "PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab", "status": "WITHDRAWN", "last_update": "2011-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145209", "title": "Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL", "status": "COMPLETED", "last_update": "2023-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01171378", "title": "Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome", "status": "COMPLETED", "last_update": "2018-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191190", "title": "Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217749", "title": "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01239394", "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01243190", "title": "Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01244451", "title": "GIMEMA CLL0809 Study (BendOfa)", "status": "COMPLETED", "last_update": "2019-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01258933", "title": "Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy", "status": "TERMINATED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01310101", "title": "Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01313689", "title": "Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01352312", "title": "Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma", "status": "TERMINATED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361711", "title": "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01444716", "title": "Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01455051", "title": "Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation", "status": "COMPLETED", "last_update": "2022-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01496976", "title": "Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497496", "title": "Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2021-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515176", "title": "Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520922", "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)", "status": "COMPLETED", "last_update": "2017-01-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01532700", "title": "An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01563055", "title": "A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580228", "title": "A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)", "status": "COMPLETED", "last_update": "2017-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612988", "title": "Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL", "status": "TERMINATED", "last_update": "2018-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659021", "title": "Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01659047", "title": "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2012-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01678430", "title": "A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment", "status": "UNKNOWN", "last_update": "2012-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01681563", "title": "Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01716208", "title": "Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01762202", "title": "Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809847", "title": "Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation", "status": "COMPLETED", "last_update": "2016-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01848145", "title": "Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004522", "title": "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049515", "title": "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135133", "title": "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137889", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients", "status": "TERMINATED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02388048", "title": "Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614508", "title": "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689141", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)", "status": "COMPLETED", "last_update": "2020-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280160", "title": "Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab", "status": "UNKNOWN", "last_update": "2022-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ORELABRUTINIB": { "n": 3, "n_observational": 3, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06378138", "title": "ICP-248 in Combination With Orelabrutinib in Treatment-na\u00efve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)", "status": "RECRUITING", "last_update": "2025-11-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322733", "title": "Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL", "status": "UNKNOWN", "last_update": "2022-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PARSACLISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2026-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PIRTOBRUTINIB": { "n": 34, "n_observational": 1, "n_active": 29, "n_withdrawn": 1, "trials": [ { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05254743", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05602363", "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2025-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643235", "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043674", "title": "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333262", "title": "Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06466122", "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06588478", "title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06812715", "title": "Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06876649", "title": "A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06876662", "title": "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973187", "title": "A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218341", "title": "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07342478", "title": "ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428707", "title": "Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07516093", "title": "Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685717", "title": "Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849416", "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965493", "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05023980", "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024045", "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers", "status": "COMPLETED", "last_update": "2026-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317936", "title": "Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax", "status": "TERMINATED", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677919", "title": "Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839872", "title": "A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162181", "title": "Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624799", "title": "Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796373", "title": "Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RITUXIMAB": { "n": 183, "n_observational": 17, "n_active": 14, "n_withdrawn": 13, "trials": [ { "nct": "NCT02727803", "title": "Personalized NK Cell Therapy in CBT", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03986034", "title": "Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644183", "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139873", "title": "A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00001586", "title": "Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis", "status": "COMPLETED", "last_update": "2013-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "status": "COMPLETED", "last_update": "2023-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003356", "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003659", "title": "Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003963", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004040", "title": "Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004112", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005601", "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00007852", "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012298", "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022971", "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058227", "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058292", "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062296", "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072514", "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080886", "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086203", "title": "Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086775", "title": "Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00087425", "title": "Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00090051", "title": "FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103558", "title": "Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104858", "title": "Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00131313", "title": "Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.", "status": "UNKNOWN", "last_update": "2005-08-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143065", "title": "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143559", "title": "Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies", "status": "COMPLETED", "last_update": "2009-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00145613", "title": "Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies", "status": "COMPLETED", "last_update": "2009-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00201682", "title": "Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00201721", "title": "Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244946", "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244985", "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00254410", "title": "FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years", "status": "COMPLETED", "last_update": "2019-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265915", "title": "Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2014-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265928", "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2008-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274989", "title": "Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00275054", "title": "Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00280241", "title": "Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281918", "title": "Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281983", "title": "Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2017-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00286780", "title": "Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2010-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00288067", "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2014-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330252", "title": "Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337246", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343447", "title": "Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2012-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381004", "title": "FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00383994", "title": "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2019-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00391066", "title": "Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410982", "title": "Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00448019", "title": "FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2015-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00473551", "title": "Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2011-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496873", "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00504491", "title": "R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2011-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513747", "title": "Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2020-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517218", "title": "This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)", "status": "WITHDRAWN", "last_update": "2008-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525603", "title": "CFAR Study in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536341", "title": "Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2017-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00543114", "title": "Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL", "status": "TERMINATED", "last_update": "2016-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00545714", "title": "A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546377", "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551239", "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00564512", "title": "Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP", "status": "COMPLETED", "last_update": "2013-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577278", "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan", "status": "COMPLETED", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00602459", "title": "Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00602836", "title": "Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00612612", "title": "Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00628238", "title": "Multi-center Trial of Revlimid\u00ae and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)", "status": "UNKNOWN", "last_update": "2010-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00636155", "title": "EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2012-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00645606", "title": "Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691652", "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738374", "title": "A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738829", "title": "Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL", "status": "COMPLETED", "last_update": "2013-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00758693", "title": "Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)", "status": "WITHDRAWN", "last_update": "2012-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759603", "title": "Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759798", "title": "Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00764517", "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "status": "TERMINATED", "last_update": "2015-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783367", "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00801060", "title": "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860457", "title": "Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00877214", "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas", "status": "UNKNOWN", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00880815", "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant", "status": "COMPLETED", "last_update": "2019-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00892827", "title": "Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2010-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00939328", "title": "S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment", "status": "WITHDRAWN", "last_update": "2015-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00946023", "title": "Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab", "status": "TERMINATED", "last_update": "2018-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00974233", "title": "Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL", "status": "COMPLETED", "last_update": "2019-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00991211", "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010061", "title": "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01010217", "title": "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide", "status": "COMPLETED", "last_update": "2020-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01027000", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044745", "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer", "status": "TERMINATED", "last_update": "2023-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01056510", "title": "A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116232", "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation", "status": "TERMINATED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01118234", "title": "Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)", "status": "COMPLETED", "last_update": "2020-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01119794", "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab", "status": "TERMINATED", "last_update": "2015-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01123356", "title": "Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab", "status": "COMPLETED", "last_update": "2015-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125176", "title": "Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01181258", "title": "Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2018-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253460", "title": "Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)", "status": "TERMINATED", "last_update": "2019-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01263704", "title": "A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01283386", "title": "A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status", "status": "TERMINATED", "last_update": "2019-03-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01290549", "title": "A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma", "status": "COMPLETED", "last_update": "2017-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292135", "title": "Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2014-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292603", "title": "A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326702", "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "status": "COMPLETED", "last_update": "2017-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01369849", "title": "Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2017-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01370772", "title": "Intensified Rituimab Prephase Before FCR in Untreated B-CLL", "status": "COMPLETED", "last_update": "2016-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01373229", "title": "Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2018-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01381692", "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01410513", "title": "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01416974", "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab", "status": "COMPLETED", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01424982", "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01465230", "title": "Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2014-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471067", "title": "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2017-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01516580", "title": "Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients", "status": "COMPLETED", "last_update": "2026-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520519", "title": "Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520922", "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)", "status": "COMPLETED", "last_update": "2017-01-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521689", "title": "Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment", "status": "UNKNOWN", "last_update": "2015-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01539512", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01558167", "title": "A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2018-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576588", "title": "Rituximab in Pretreated Elderly or Unfit B-CLL Patients", "status": "COMPLETED", "last_update": "2019-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01611090", "title": "A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01619761", "title": "NK Cells in Cord Blood Transplantation", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01625741", "title": "Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy", "status": "TERMINATED", "last_update": "2015-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01670812", "title": "Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2012-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682616", "title": "A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723839", "title": "Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744626", "title": "Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2016-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "status": "COMPLETED", "last_update": "2016-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980888", "title": "Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "status": "COMPLETED", "last_update": "2022-04-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01998880", "title": "CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007044", "title": "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013817", "title": "CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02168907", "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213913", "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02232386", "title": "Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02251548", "title": "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02259348", "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation", "status": "TERMINATED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02265731", "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02280525", "title": "Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma", "status": "COMPLETED", "last_update": "2023-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02420938", "title": "Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients", "status": "WITHDRAWN", "last_update": "2016-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02594384", "title": "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2017-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657447", "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02933320", "title": "BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia", "status": "COMPLETED", "last_update": "2021-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02960646", "title": "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2023-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003546", "title": "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03524235", "title": "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639324", "title": "Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL", "status": "WITHDRAWN", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03788291", "title": "Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823365", "title": "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2021-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155840", "title": "Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578613", "title": "ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL", "status": "UNKNOWN", "last_update": "2023-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04843904", "title": "Safe Accelerated Venetoclax Escalation in CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04981912", "title": "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069051", "title": "Belimumab in Patients with Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209308", "title": "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL", "status": "WITHDRAWN", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06970743", "title": "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220187", "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SPEBRUTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01732861", "title": "Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2019-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744626", "title": "Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2016-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TAFASITAMAB": { "n": 8, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05943496", "title": "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01161511", "title": "Safety and Tolerability of XmAb\u00ae5574 in Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2014-04-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005289", "title": "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2026-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718869", "title": "Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TENALISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04204057", "title": "Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TIRABRUTINIB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01659255", "title": "Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL", "status": "COMPLETED", "last_update": "2021-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02968563", "title": "Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983617", "title": "Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISAGENLECLEUCEL": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02529813", "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TOSITUMOMAB": { "n": 3, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022880", "title": "Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2005-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476047", "title": "Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission", "status": "COMPLETED", "last_update": "2017-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOSITUMOMAB 131I": { "n": 2, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476047", "title": "Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission", "status": "COMPLETED", "last_update": "2017-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "UBLITUXIMAB": { "n": 19, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01098188", "title": "LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2012-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01647971", "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2022-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744912", "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2022-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006485", "title": "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies", "status": "COMPLETED", "last_update": "2019-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013128", "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02301156", "title": "Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2022-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02535286", "title": "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation", "status": "COMPLETED", "last_update": "2022-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02612311", "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02656303", "title": "A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207256", "title": "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671590", "title": "Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies", "status": "TERMINATED", "last_update": "2024-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "status": "TERMINATED", "last_update": "2024-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04149821", "title": "Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy", "status": "TERMINATED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "UMBRALISIB": { "n": 19, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01767766", "title": "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2021-08-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006485", "title": "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies", "status": "COMPLETED", "last_update": "2019-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02100852", "title": "TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2019-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02268851", "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02535286", "title": "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation", "status": "COMPLETED", "last_update": "2022-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02612311", "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02656303", "title": "A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02742090", "title": "Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy", "status": "TERMINATED", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207256", "title": "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671590", "title": "Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies", "status": "TERMINATED", "last_update": "2024-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "status": "TERMINATED", "last_update": "2024-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04149821", "title": "Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy", "status": "TERMINATED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04163718", "title": "TGR-1202 (Umbralisib) in Treatment Na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "TERMINATED", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VECABRUTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03037645", "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers", "status": "TERMINATED", "last_update": "2020-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VELTUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00546793", "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL", "status": "COMPLETED", "last_update": "2021-08-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VENETOCLAX": { "n": 135, "n_observational": 22, "n_active": 78, "n_withdrawn": 7, "trials": [ { "nct": "NCT03986034", "title": "Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04269902", "title": "Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523428", "title": "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560322", "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588922", "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758975", "title": "Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895436", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941716", "title": "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091424", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168930", "title": "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183854", "title": "Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05197192", "title": "A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336812", "title": "Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388006", "title": "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na\u00efve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791409", "title": "Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL", "status": "RECRUITING", "last_update": "2024-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05947851", "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06466122", "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644183", "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06846671", "title": "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014917", "title": "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024706", "title": "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i \u00b1 Obinutuzumab", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154264", "title": "A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218510", "title": "Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07520006", "title": "Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07734038", "title": "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01328626", "title": "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2022-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01671904", "title": "A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682616", "title": "A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2023-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685892", "title": "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "status": "COMPLETED", "last_update": "2021-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02005471", "title": "A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141282", "title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242942", "title": "Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02265731", "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2021-09-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02427451", "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02640833", "title": "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor", "status": "WITHDRAWN", "last_update": "2016-07-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756611", "title": "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2023-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756897", "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02758665", "title": "Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846623", "title": "Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02910583", "title": "Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)", "status": "COMPLETED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950051", "title": "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02966756", "title": "A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980731", "title": "A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).", "status": "COMPLETED", "last_update": "2023-02-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045328", "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226301", "title": "A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations", "status": "UNKNOWN", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03343678", "title": "This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax", "status": "WITHDRAWN", "last_update": "2018-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455517", "title": "Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462719", "title": "A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03467867", "title": "A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492125", "title": "A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513562", "title": "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03534323", "title": "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03547115", "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML", "status": "TERMINATED", "last_update": "2026-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576547", "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609593", "title": "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639324", "title": "Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL", "status": "WITHDRAWN", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701282", "title": "Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708003", "title": "Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL", "status": "TERMINATED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737981", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739554", "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755947", "title": "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766763", "title": "Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787264", "title": "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "status": "TERMINATED", "last_update": "2024-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836261", "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844048", "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884972", "title": "Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor", "status": "WITHDRAWN", "last_update": "2023-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03943342", "title": "Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010968", "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04016805", "title": "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285567", "title": "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419389", "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419519", "title": "Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447768", "title": "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04501939", "title": "Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512105", "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "status": "TERMINATED", "last_update": "2025-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04608318", "title": "Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623541", "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04754035", "title": "Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04790045", "title": "Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04843904", "title": "Safe Accelerated Venetoclax Escalation in CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965493", "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04981912", "title": "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057494", "title": "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069051", "title": "Belimumab in Patients with Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105841", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "COMPLETED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209308", "title": "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL", "status": "WITHDRAWN", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317936", "title": "Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax", "status": "TERMINATED", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433532", "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677919", "title": "Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963074", "title": "A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "WITHDRAWN", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07082452", "title": "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Na\u00efve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07557056", "title": "Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07582159", "title": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690891", "title": "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07691047", "title": "Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738887", "title": "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VOXTALISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01403636", "title": "A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2016-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01410513", "title": "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2016-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": { "n": 13, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012298", "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031642", "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2023-12-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00033423", "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058292", "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00119392", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392691", "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00438880", "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577278", "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan", "status": "COMPLETED", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01490723", "title": "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)", "status": "COMPLETED", "last_update": "2020-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANDELISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT05209308", "title": "Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL", "status": "WITHDRAWN", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANUBRUTINIB": { "n": 49, "n_observational": 4, "n_active": 39, "n_withdrawn": 0, "trials": [ { "nct": "NCT03666000", "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168930", "title": "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643235", "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05873712", "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06520098", "title": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "RECRUITING", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544785", "title": "Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651970", "title": "Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06697184", "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735664", "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation", "status": "RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06812715", "title": "Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839053", "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958705", "title": "Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07052695", "title": "Mosunetuzumab for CLL MRD Clearance", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271667", "title": "A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07321652", "title": "Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671378", "title": "A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Na\u00efve, High-Risk CLL/SLL Patients", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07734038", "title": "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914938", "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2023-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03206918", "title": "Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734016", "title": "A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2025-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03824483", "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116437", "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172246", "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282018", "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab", "status": "COMPLETED", "last_update": "2026-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458610", "title": "Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04515238", "title": "Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287984", "title": "Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL", "status": "UNKNOWN", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05478512", "title": "Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718869", "title": "Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367374", "title": "MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547944", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06637501", "title": "A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003464", "title": "Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674810", "title": "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07682415", "title": "Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL\uff1aStop Trial 2.0", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739459", "title": "Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07812246", "title": "Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }